Correlation Between Mineralys Therapeutics, and Allovir

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Allovir at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Allovir into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Allovir, you can compare the effects of market volatilities on Mineralys Therapeutics, and Allovir and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Allovir. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Allovir.

Diversification Opportunities for Mineralys Therapeutics, and Allovir

0.37

Correlation Coefficient

Mineralys Therapeutics,  Allovir

Weak diversification

The 3 months correlation between Mineralys and Allovir is 0.37. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Allovir in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allovir and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Allovir. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allovir has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Allovir go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Allovir

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 1.21 times more return on investment than Allovir. However, Mineralys Therapeutics, is 1.21 times more volatile than Allovir. It trades about 0.06 of its potential returns per unit of risk. Allovir is currently generating about -0.27 per unit of risk. If you would invest  1,148  in Mineralys Therapeutics, Common on September 16, 2024 and sell it today you would earn a total of  42.00  from holding Mineralys Therapeutics, Common or generate 3.66% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Allovir

Mineralys Therapeutics,

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Allovir

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Allovir has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Mineralys Therapeutics, and Allovir

The main advantage of trading using opposite Mineralys Therapeutics, and Allovir positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Allovir can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will offset losses from the drop in Allovir's long position.

The idea behind Mineralys Therapeutics, Common and Allovir pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.